Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

34.22

+1.01 (3.04%)

as of Jun 24, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 24, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical, represented by the symbol TEVA-N, is currently experiencing a robust demand for GLP (glucose-lowering agents), although the entry of more generics may lead to price declines in this sector. The company has shown a remarkable recovery under its current CEO, boasting a 264% increase since January 2023, suggesting it's on a promising turnaround. Its headquarters are located in Israel, and it holds a strong position as a large-cap pharmaceutical company, ranking #1 in its ADR/CDR universe among international stocks. Following a breakout over $21 in September, Teva has seen significant accumulation over the past six months, although it does not pay dividends. Analysts remain optimistic, with a price target of $34.50.

Consensus

positive

Valuation

undervalued

Similar

Roche, RHHBY

DON'T BUY

Once generic stocks have their products in place they can milk it for several years to come. He wouldn't be looking at this right now.

PAST TOP PICK

(A Top Pick July 21/08. Up 14.55%.)

TOP PICK

Has 25% of the US generic drug market. Generics will gain with the government’s new health plans. Trades at about 15X earnings. Long record of successfully increasing earnings and dividends.

BUY

Largest generic drug manufacturer globally. Grows through patents coming off existing drugs and by making acquisitions. Have also developed a number of drugs on their own.

TOP PICK

Countries everywhere will be looking at ways of cutting back on drug costs. This is the biggest generic drug company globally. A defensive sector.

TOP PICK

During the bear market decline, this stock held in like a rock. It's both defensive and growth. Selling at less than half of its 30% growth rate. Hitting on all cylinders.

TOP PICK

World's largest drug market and will benefit from US push to lower health care costs. Likes it for growth. Likely to see 30% in short term. Biggest risk is the development of new drug candidates.

TOP PICK

World’s largest generic manufacturer. With their Barr acquisition they now have 25% of the US generic market and 17% of the total prescription market. This is in an era where it looks like the US administration is moving to a more nationalized health care plan

TOP PICK

Worlds largest maker of generic drugs. US administration is likely to push forward towards greater use of generics that would give them a $9.2 billion savings over the next 10 years. This company will be a beneficiary. Made an acquisition last year of Barr Pharmaceuticals, which will give them good synergies.

TOP PICK

Israeli-based pharmaceutical company. Recently completed an acquisition of US Barr Pharmaceuticals giving them the largest share (25%) of the generic market in the US. US healthcare focus on generics is going to increase. Leader in producing new generics and is able to negotiate better prices for its products. Earnings in 2010 are expected to increase by more than 30%. Small but growing dividend.

PAST TOP PICK

(A Top Pick Feb 26/02. Down 10.2%.)

TOP PICK

Generic drugs. Manufactures more than 25% of the US market. In a move to more universal medicine in the US, generic manufacturers are going to be big beneficiaries. Earnings are likely to increase by 50% in the 2009 to 2012 period. Trading at 15X earnings.

COMMENT

(Market Call Minute.) Likes this as a company. In the very short run the health care stocks are under performing in the last couple of weeks. If you like pharmaceuticals, this is one that you could purchase.

DON'T BUY

Outsource pharmaceutical manufacturer of generic drugs. No barriers to stop others from doing the same kind of business. He prefers Johnson & Johnson (JNJ-N) or Novartis (NVS-N) who specialize in what they do.

BUY

Trading down 5% on a one-year basis and 14 X forward earnings. This would be a more conservative buy then Gilead (GILD-Q).

Showing 196 to 210 of 275 entries

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)